About Open Access
A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors
Lookup NU author(s)
Professor Ruth Plummer
Professor Alan Calvert
Plummer ER, Vidal L, Perrett RH, Shaw H, Pilkington M, Hanwell J, Temple G, Fong P, Amelsberg A, Calvert AH, de Bono J
Clinical Cancer Research
24 Part 2 Supplement S
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Conference: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics Philadelphia, PA, 14-18 November 2005.
Newcastle University Library, NE2 4HQ, United Kingdom. Tel: 0044 (191) 208 2920
©2017 Newcastle University Library